Secondary progressive multiple sclerosis

Summary

Secondary progressive multiple sclerosis (MONDO:0000450) is a disease and 70 clinical trials. Top therapeutic interventions include siponimod, fexofenadine, and natalizumab. A subtype of chronic progressive multiple sclerosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 70

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	secondary progressive multiple sclerosis
Mondo ID	MONDO:0000450
EFO	EFO:0008522
DOID	DOID:0050783
ICD-11	1045965709
SNOMED CT	425500002
UMLS	C0751965
MedGen	155969
Is cancer (heuristic)	no

Also known as: secondary-progressive MS · SPMS

Disease family

This is a subtype of chronic progressive multiple sclerosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › autoimmune disorder of central nervous system › multiple sclerosis › chronic progressive multiple sclerosis › secondary progressive multiple sclerosis

Related subtypes (2): primary progressive multiple sclerosis, progressive relapsing multiple sclerosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 8 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Ocrelizumab	Approved (phase 4)
Dalfampridine	Phase 3 (in late-stage trials)
Dirucotide	Phase 3 (in late-stage trials)
Mitoxantrone	Phase 3 (in late-stage trials)
Natalizumab	Phase 3 (in late-stage trials)
Simvastatin	Phase 3 (in late-stage trials)
Siponimod	Phase 3 (in late-stage trials)
Teriflunomide	Phase 3 (in late-stage trials)
Tolebrutinib	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Amiloride, Corticotropin, Estriol, Fluoxetine, Glatiramer Acetate, Lamotrigine, Lipoic Acid, Alpha, Norethindrone, Riluzole, Rituximab, Sodium Chloride.

Clinical trials & evidence

Clinical trials

Clinical trials: 70.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	23
PHASE2	14
PHASE3	10
PHASE1	9
PHASE1/PHASE2	6
PHASE2/PHASE3	4
PHASE4	2
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02208050	PHASE4	COMPLETED	A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS
NCT04792567	PHASE4	COMPLETED	Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
NCT04047628	PHASE3	RECRUITING	Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
NCT04688788	PHASE3	ACTIVE_NOT_RECRUITING	Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
NCT06372145	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT07225504	PHASE3	RECRUITING	A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07299019	PHASE3	RECRUITING	A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT00146159	PHASE3	TERMINATED	Study Evaluating Mitoxantrone in Multiple Sclerosis
NCT00869726	PHASE2/PHASE3	COMPLETED	A Study for Patients With Secondary Progressive Multiple Sclerosis
NCT00870155	PHASE2/PHASE3	TERMINATED	A Study for Patients With Multiple Sclerosis
NCT01416181	PHASE3	TERMINATED	A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
NCT01665144	PHASE3	COMPLETED	Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
NCT01917019	PHASE3	COMPLETED	A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
NCT03315923	PHASE2/PHASE3	COMPLETED	Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients
NCT03387670	PHASE3	COMPLETED	Multiple Sclerosis-Simvastatin Trial 2
NCT04925557	PHASE2/PHASE3	TERMINATED	Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis
NCT05893225	PHASE2	ACTIVE_NOT_RECRUITING	Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration
NCT06292923	PHASE2	RECRUITING	A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
NCT06599307	PHASE2	RECRUITING	The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
NCT06961383	PHASE2	NOT_YET_RECRUITING	Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis
NCT07477639	PHASE1/PHASE2	RECRUITING	Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT00257855	PHASE2	COMPLETED	A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
NCT00647348	PHASE2	COMPLETED	Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis
NCT01077466	PHASE2	COMPLETED	Natalizumab Treatment of Progressive Multiple Sclerosis
NCT01181089	PHASE1/PHASE2	WITHDRAWN	Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
NCT01191996	PHASE1/PHASE2	COMPLETED	Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
NCT01228396	PHASE2	UNKNOWN	AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis
NCT01466114	PHASE2	UNKNOWN	Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
NCT01684761	PHASE2	COMPLETED	Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
NCT01910259	PHASE2	COMPLETED	MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
NCT01950234	PHASE2	TERMINATED	ACTH in Progressive Forms of MS
NCT02228213	PHASE2	COMPLETED	Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis
NCT02495766	PHASE1/PHASE2	COMPLETED	Autologous Mesenchymal Stromal Cells for Multiple Sclerosis
NCT03283826	PHASE1/PHASE2	TERMINATED	Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
NCT03696485	PHASE1/PHASE2	WITHDRAWN	Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS
NCT03896217	PHASE2	COMPLETED	Simvastatin in Secondary Progressive Multiple Sclerosis
NCT03783416	PHASE1	RECRUITING	SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
NCT00559702	PHASE1	COMPLETED	Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
NCT00813969	PHASE1	COMPLETED	Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
NCT02253264	PHASE1	COMPLETED	A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SIPONIMOD	4	6
FEXOFENADINE	4	3
NATALIZUMAB	4	3
OCRELIZUMAB	4	3
AMILORIDE	4	1
CORTICOTROPIN	4	1
DALFAMPRIDINE	4	1
ELASOMERAN	4	1
ESTRIOL	4	1
FERUMOXYTOL	4	1
GADOTERIDOL	4	1
GLATIRAMER ACETATE	4	1
LAMOTRIGINE	4	1
MITOXANTRONE	4	1
NORETHINDRONE	4	1
RILUZOLE	4	1
TERIFLUNOMIDE	4	1
DIRUCOTIDE	3	2
LIPOIC ACID, ALPHA	3	1
ORELABRUTINIB	3	1
REMIBRUTINIB	3	1
TOLEBRUTINIB	3	1
TRICAPRILIN	3	1
BAMINERCEPT	2	1
EVRULEUCEL	2	1
CHEMBL4082273	0	1
CHEMBL4579631	0	1
CHEMBL4776881	0	1
IMILECLEUCEL-T	-1	1